CME/CE - Global Oncology Academy

Episodes 17-32 of 103

Significance of HER2 Expression in Solid Tumors
Significance of HER2 Expression in Solid Tumors
MinuteCE®
Significance of HER2 Expression in Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
MinuteCE®
Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
MinuteCE®
HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps
0.75 program credits
- Shubham Pant, MD, MBBS
0.75 program credits
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Diversity in HER2 Expression Among Gynecologic Cancers
Diversity in HER2 Expression Among Gynecologic Cancers
MinuteCE®
Diversity in HER2 Expression Among Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
MinuteCE®
Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents
0.75 program credits
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 program credits
MinuteCE®
Expanding Horizons: HER2 Targeting in Metastatic Solid Tumors
0.75 credits 8 episodes
- Shubham Pant, MD, MBBS
- Ritu Salani, MD, MBA
0.75 credits 8 episodes
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
MinuteCE®
Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
MinuteCE®
Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers
0.75 program credits
- Ritu Salani, MD, MBA
0.75 program credits
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
Project Oncology®
Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care
- Saad Z. Usmani, MD, MBA, FACP
- Joshua Richter, MD
- Ashley Steinberger, APP
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CE
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
0.25 credits
- Jennifer Caudle, DO
- Patricia A. Mangan, RN, MSN, APRN-BC
0.25 credits
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
CME/CE Broadcast Replay
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
1.00 credit
- Jennifer Caudle, DO
- Patricia A. Mangan, RN, MSN, APRN-BC
1.00 credit
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
MinuteCE®
Practice Changing Highlights in G/GEJ Cancers: The Latest Data from Chicago
1.25 program credits
- Samuel J. Klempner, MD
1.25 program credits
WHIM Syndrome Management: The First FDA Approval for Patients
WHIM Syndrome Management: The First FDA Approval for Patients
MinuteCE®
WHIM Syndrome Management: The First FDA Approval for Patients
1.00 program credit
- Teresa K. Tarrant, MD
1.00 program credit
WHIM Syndrome: A Chronic Neutropenic Disorder
WHIM Syndrome: A Chronic Neutropenic Disorder
MinuteCE®
WHIM Syndrome: A Chronic Neutropenic Disorder
1.00 program credit
- Peter E. Newburger, MD
1.00 program credit
WHIM Syndrome: A Misguided Immune System!
WHIM Syndrome: A Misguided Immune System!
MinuteCE®
WHIM Syndrome: A Misguided Immune System!
1.00 program credit
- Peter E. Newburger, MD
1.00 program credit

2/7